PRODUCTS
ENABLING A HEALTHIER WORLD
We bring to the table an ever-expanding array of diverse therapeutic and biosimilar products and solutions embedded with the capability of improving patient outcomes and addressing unmet medical needs. Explore our portfolio and discover how our advanced treatments are making a positive impact in the field of biopharmaceuticals. Click on each item to learn more…
Metabolic Disorders
Glargine | Lispro | Aspart | Insulin | Liraglutide | Semaglutide | Parathyroid Hormone
Oncology
Pembrolizumab | Nivolimumab | Pertuzumab
Anti-inflammatory
Ustekinumab
Immunosuppressor
Golimumab
Equipment
Sartorius Twin 5 & 10L Fermenter
Sartorius Twin 5 & 10L Bioreactor
Sartorius 20L Insitu Fermenter
IKA 5L Bioreactor
Incubator
Skakers X 2
Thermo CO2 Incubators X 2
Akta Pilot
Biorad NGC
Novasep RPHPLC
Waters
HPLC X 2
Waters UPLC X 2
Shimadzu HPLC X 2
Multimode Reader ID3 Molecular Device
RT PCR Thermo
Biacore T200
Sciex Beckman
Nova Bioanalyzer
Seimens Rapid Point 500
Centrifuge 6L X2
Biosafety Cabinets X 2
Olympus Microscope X 2
Thermo - 80 Freezers X 2
Liquid Nitrogen systems X 4
Our pipeline is varied and encompasses important work:
Glargine
Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used for the treatment of hyperglycemia caused by type I and type II diabetes. It has a duration of action upto 24 hours allowing for once-daily dosing, typically at bedtime.
Lispro
Insulin lispro is a rapid-acting form of insulin, sold under the brand name Humalog among others, is a modified type of medical insulin used for the treatment of hyperglycemia caused by type I and type II diabetes. It begins to exert its effects within 15 minutes of subcutaneous administration.
Aspart
Insulin aspart is a rapid-acting form of insulin, sold under the brand name NovoLog and Fiasp, among others, , is a modified type of medical insulin used for the treatment of hyperglycemia caused by type I and type II diabetes. It begins to exert its effects within 15 minutes of subcutaneous administration.
Insulin
Liraglutide
Semaglutide
Parathyroid Hormone
Pembrolizumab
Pembrolizumab, sold under the brand name Keytruda, is PD-1 blocking humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.
Nivolimumab
Nivolumab, sold under the brand name OPDIVO, is a PD-1 blocking antibody used to treat melanoma, non-small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
Pertuzumab
Ustekinumab
Golimumab
Golimumab, sold under the brand name Simponi, is a human IgG1 kappa monoclonal antibody which is used as an immunosuppressive medication. It is a TNF-alpha inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
